PRESS RELEASES

 

IMPROVING CANCER SURVIVAL PREDICTION: A NEW APPROACH WITH EPIVAX THERAPEUTICS’ ANCER PLATFORM

May 13, 2021

PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method of survival analysis for cancer patients using EVT’s Ancer platform.